SEQUOIA – Results in Arm D

The SEQUOIA Arm D study explored the combination of zanubrutinib and venetoclax for untreated CLL/SLL patients, including those with abnormal TP53. Both normal and abnormal TP53 cohorts showed high response rates, with a 60% undetectable minimal residual disease (uMRD) rate. Longer treatment improved uMRD conversion, especially in high-risk patients. The therapy was well-tolerated, and the safety profile aligned with expectations. Ongoing follow-up is needed to assess long-term outcomes for patients who stop treatment.